Piper Sandler rated the Liminal BioSciences Inc. (NASDAQ: LMNL) stock “an Overweight” and gave the company’s common stock a price target of $22. Piper Sandler’s estimates were contained in a research note released on Monday, December 21, 2020. Several other experts on Wall Street have posted such reports regarding the LMNL shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Wall Street analysts tracking the Liminal BioSciences Inc. (NASDAQ: LMNL) stock on daily basis. Out of 3 analysts, 1 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT. Another 2 recommended that LMNL is a HOLD, while 0 rated it UNDERWEIGHT and the same number recommended SELL. If we look at the broader picture, the above ratings give the stock an average analyst rating of 2.70.
Liminal BioSciences Inc. has a market valuation of $159.23 million and last released its earnings reports on 03/31/2021, for the quarterly period ended on 9/29/2020. The company’s revenue for the quarter stood at $479.5 million. LMNL Company also reported its earnings per share (EPS) as -$0.76 for the quarter, which beat consensus estimates by analysts of -$0.78 by $0.02, surprisingly 2.60% higher.
The stock market has more often than not ended up being extremely baffling, catching even some of the more experienced traders by surprise. It happens that even when results are as projected, the market sometimes just takes a sudden turn towards the opposite direction. Often such events lead to doubt and much speculation. At such time, it may pay to keep tabs on a stock’s historical price performance. Useful also would be knowledge of the stock’s trends, both the short term and long-term. Liminal BioSciences Inc. (NASDAQ: LMNL) share prices have increased by 31.18% over the past week, but are down -28.96% over prices posted in the last quarter. Going further back, the stock’s price has gone over -56.31% over the last 6 months but is up 30.24% in year-to-date trading.
A recent spot check on the stock’s support and resistance revealed that the publicly-traded Liminal BioSciences Inc. (NASDAQ: LMNL) shares are trading at a price close to -29.69% lower than its 90-day high. On the other hand, the stock is +55.84% away from its low in the 90-day period. More broadly, LMNL’s current price is -82.61% away from 52-week high. The price is 55.84% above from its 52-week low.
A look at another ratio shows that Liminal BioSciences Inc. has a Return on Investment (ROI) of -149.30%. When profits exceed costs, then the ROI percentage will be positive, and analysts will rate such business as having a net gain. However, if the percentage index is negative, then the company’s costs basically outweigh profits.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 13.37%, and 11.21% for the month. This stock’s Average True Range (ATR) currently stands at 0.51, with the beta factor poised at 1.82. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, means that the stock’s volatility at that particular moment is low.
Shares of the Liminal BioSciences Inc. (NASDAQ: LMNL) gained by $0.38 during Friday’s regular trading session to climb to $5.47. The company had a daily trading volume of 1.55 million shares, higher than its average intra-day trading volumes of about 1.34M shares.